Recently, Jiangsu Academy of Science and Technology for Development released the list of "2019 Top 100 Innovative Enterprises in Jiangsu Province". Hansoh Pharma was once again selected and ranked ninth. This is Hansoh Pharma's third time on the list, demonstrating its innovation strength and vigorous innovative development trend.

Scientific and technological innovation has been the core competitiveness of Hansoh Pharma and the internal driving force of its rapid and steady development. It has been on the list of Top 100 Innovative Enterprises in Jiangsu Province for three times and was even ranked among the top ten in 2019, which shows that Hansoh Pharma's innovation achievements and enterprise strength are constantly being confirmed and recognized. The selection of "2019 Top 100 Innovative Enterprises in Jiangsu Province" was mainly based on the key elements and main links of enterprise innovation. Qualitative and quantitative indicators that could effectively reflect the level of innovation development were determined, the evaluation system was developed, and the level of innovation development of enterprises was comprehensively evaluated from four aspects: innovation input, innovation output, innovation performance and innovation management. From 2016 to now, Jiangsu Academy of Science and Technology for Development has released the list of top 100 innovative enterprises for four consecutive times. The top 100 innovative enterprises released this time have four distinct characteristics: strong independent innovation capability, good economic benefits, great influence in the industry and high level of innovation management. Among them, 90% are either high-tech enterprises or have core subsidiaries that are high-tech enterprises.

As a leading innovation-driven pharmaceutical company in China, Hansoh Pharma has set up R&D centers in Shanghai, Lianyungang, and Changzhou, as well as a number of national-level R&D facilities, and has continuously increased its R&D investment year by year. With its superior R&D strength and more than 20 years of R&D experience, Hansoh Pharma has undertaken more than 40 national-level scientific research projects including 863 Program, "Major New Drug Innovation and Development" Science and Technology Special Project, and Torch Program; has won 2 second prizes in the National Scientific and Technological Progress Award and 1 gold medal in China Patent Award; has been granted more than 200 invention patents at home and abroad; and has participated in the formulation of nearly 150 national standards. Up to the first half of 2020, Hansoh Pharma has launched four Class 1 innovative drugs: Ameile (Ametinib Mesylate Tablets), Hansoh Xinfu (Flumatinib Mesylate Tablets), Fulaimei (Polyethylene Glycol Loxenatide Injection), and Mailingda (Morinidazole and Sodium Chloride Injection). In addition, Hansoh Pharma has been dynamically aligned with the global advanced access level by continuously designing and building production facilities and lines in accordance with international advanced standards and using advanced production equipment. The Company's production quality system has been officially certified by FDA of the United States, EMA of the European Union and PMDA of Japan, and its finished preparations and APIs have been approved for sale in Europe, America, Japan, etc.

Adhering to its corporate mission to "create excellence in pharmaceuticals, enhance innovation in China", Hansoh Pharma has been focused on independent innovation and committed to meeting the unmet medical needs of patients. As a leading pharmaceutical enterprise in China, Hansoh Pharma will, as always, accelerate the pace of scientific and technological innovation, shoulder its due responsibilities, and contribute wisdom and strength to the "Healthy China" strategy.